Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China-Reference-Cited by-同舟云学术

Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China

Published:2023-11-16 Issue: Volume: Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Liu Ying¹²³⁴,Zhang Jiayou⁵⁶,Liu Wen¹²³,Pan Yongbing⁵⁶,Ruan Shunan¹²,Nian Xuanxuan⁵⁶,Chen Wei⁵⁶,Sun Lina⁷,Yin Qiangling⁷⁸,Yue Xin⁵⁶,Li Qingliang⁵⁶,Gui Fang⁵⁶,Wu Cong⁵⁶,Wang Shuzhen¹²,Yang Yunkai⁹,Jing Zhaofei⁵⁶,Long Feiguang⁹,Wang Zejun⁵⁶,Zhang Zeyu⁵⁶,Huang Chaolin¹²³⁴,Duan Kai⁵⁶,Liang Mifang⁷,Yang Xiaoming⁵⁶⁹

Affiliation:

1. Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, 430048 Wuhan, China

2. Hubei Clinical Research Center for Infectious Diseases, 430048 Wuhan, China

3. Hubei Public Health Clinical Center, 430311 Wuhan, China

4. Wuhan Research Center for Communicable Disease Diagnosis and Treatment, 430345 Wuhan, China

5. National Engineering Technology Research Center for Combined Vaccines, 430207 Wuhan, China

6. Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China

7. National Institute for Viral Disease Control and Prevention, Chinese CDC, 100052, Beijing, China.

8. Hubei Provincial Center for Disease Control and Prevention, Wuhan 430065, China.

9. China National Biotec Group Company Limited, 100029 Beijing, China

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2023.2284297

Reference37 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies

3. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies

4. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis